ArticleCancer discovery2018
Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound
Registry-linked trialOpen access · greenAbstract read
In one paragraph
Article in Cancer discovery, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07045610 (Explore the Primary Resistance Mechanisms of Anaplastic Lymphoma Kinase Inhibitors), which is not on this map. Cited by 195 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
195citing papers in PubMed, 3 pooled it
26.0field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Explore the Primary Resistance Mechanisms of Anaplastic Lymphoma Kinase Inhibitors
Who cites it
195 citing papers in PubMed, 3 syntheses or guidelines pooled it, 303 citations in OpenAlex.
- Comparing efficacy and safety of upfront treatment strategies for anaplastic lymphoma kinase-positive non-small cell lung cancer: a network meta-analysis.Exploration of targeted anti-tumor therapy · 2023Pooled it
- Non-small cell lung cancer withFrontiers in oncology · 2023Pooled it
- Impact of Smoking on Response to the First-Line Treatment of Advanced ALK-Positive Non-Small Cell Lung Cancer: A Bayesian Network Meta-Analysis.Frontiers in pharmacology · 2022Pooled it
- NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations.Cancer discovery · 2024Trial
- Safety and activity of alectinib plus bevacizumab in patients with advanced ALK-rearranged non-small-cell lung cancer: a phase I/II study.ESMO open · 2022Trial
- Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer.Targeted oncology · 2020Trial
- Trial
- Real-world evolution of first-line ALK-positive NSCLC management in Spain.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- A new chapter in targeting kinase enzymes in cancer.Nature · 2026Article
- Liquid biopsy in modern medicine: advancing diagnostics from molecular insights to clinical practice.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Article
- Review
- Systematic Targeting of Protein Complexes with Molecular COUPLrs.Cancer discovery · 2026Article
- Efficacy and safety of second-line treatments in ALK mutation-positive advanced non-small cell lung cancer after second- or third-generation ALK inhibitors: Turkish Oncology Group real-life study (TOG study).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Pyridine-containing antitumor agents: structure-oriented medicinal chemistry, structure-activity relationships, and ADMET liabilities.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2026Review
- ALK rearrangements and resistance mutations in non-small cell lung cancer: molecular mechanisms and therapeutic implications.Cancer chemotherapy and pharmacology · 2026Review
- Precision Targeting ofInternational journal of molecular sciences · 2026Review
- The novel ALK K1150dup mutation mediates resistance to frontline lorlatinib and retains sensitivity to gilteritinib.NPJ precision oncology · 2026Article
- Comparative effectiveness and cost-effectiveness of ALK-positive NSCLC sequential strategies under physician and patient preferences.Cost effectiveness and resource allocation : C/E · 2026Article
- Acquired resistance of cancer therapies: Mechanisms and perspectives.Chinese medical journal · 2026Review
135 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
25 authors at 5 institutions in 4 countries.
Satoshi YodaMassachusetts General Hospital Cancer Center, Charlestown, Massachusetts.
Jessica J LinMassachusetts General Hospital Cancer Center, Charlestown, Massachusetts.ORCID 0000-0001-7373-3916
Michael S LawrenceMassachusetts General Hospital Cancer Center, Charlestown, Massachusetts.
Benjamin J BurkePfizer Worldwide Research and Development, La Jolla, California.
Luc FribouletGustave Roussy Cancer Campus, Université Paris Saclay, INSERM U981, Paris, France.
Adam LangenbucherMassachusetts General Hospital Cancer Center, Charlestown, Massachusetts.
Leila DardaeiMassachusetts General Hospital Cancer Center, Charlestown, Massachusetts.
Kylie Prutisto-ChangMassachusetts General Hospital Cancer Center, Charlestown, Massachusetts.
Ibiayi Dagogo-JackMassachusetts General Hospital Cancer Center, Charlestown, Massachusetts.
Sergei TimofeevskiPfizer Worldwide Research and Development, La Jolla, California.
Harper HubbelingMassachusetts General Hospital Cancer Center, Charlestown, Massachusetts.ORCID 0000-0003-4812-5235
Justin F GainorMassachusetts General Hospital Cancer Center, Charlestown, Massachusetts.
Lorin A FerrisMassachusetts General Hospital Cancer Center, Charlestown, Massachusetts.
Amanda K RileyMassachusetts General Hospital Cancer Center, Charlestown, Massachusetts.
Krystina E KattermannMassachusetts General Hospital Cancer Center, Charlestown, Massachusetts.
Daria TimoninaMassachusetts General Hospital Cancer Center, Charlestown, Massachusetts.
Rebecca S HeistMassachusetts General Hospital Cancer Center, Charlestown, Massachusetts.
A John IafrateCancer Center and Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
Cyril H BenesMassachusetts General Hospital Cancer Center, Charlestown, Massachusetts.
Jochen K LennerzCancer Center and Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
Mari Mino-KenudsonCancer Center and Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
Jeffrey A EngelmanNovartis Institutes for BioMedical Research, Cambridge, Massachusetts.
Ted W JohnsonPfizer Worldwide Research and Development, La Jolla, California.
Aaron N Hata *Massachusetts General Hospital Cancer Center, Charlestown, Massachusetts. ashaw1@mgh.harvard.edu ahata@mgh.harvard.edu.
Alice T Shaw *Massachusetts General Hospital Cancer Center, Charlestown, Massachusetts. ashaw1@mgh.harvard.edu ahata@mgh.harvard.edu.
Massachusetts General Hospital · USPfizer (United States) · USBroad Institute · USInserm · FRNovartis (Switzerland) · CH
Funding
Dana Farber/Harvard Cancer Consortium Career Development Program in Clinical OncologyK12CA087723 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI David Tsai Ting · 2002 to 2026
$17.9MOvercoming Resistance Mechanisms to Anaplastic Lymphoma Kinase InhibitorsR01CA164273 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI Aaron N Hata, Jessica Jiyeong Lin · 2012 to 2026
$5.5MNCI NIH HHS K12 CA087723NCI NIH HHS R01 CA164273
Abstract
The cornerstone of treatment for advanced ALK-positive lung cancer is sequential therapy with increasingly potent and selective ALK inhibitors. The third-generation ALK inhibitor lorlatinib has demonstrated clinical activity in patients who failed previous ALK inhibitors. To define the spectrum of
Indexed as
Drug Resistance, NeoplasmMutationAminopyridinesAnaplastic Lymphoma KinaseAnimalsCell Line, TumorCrizotinibEthylnitrosoureaExome SequencingFemaleHumansLactamsLactams, MacrocyclicLung NeoplasmsMiceOncogene Proteins, FusionALK protein, humanAminopyridinesAnaplastic Lymphoma KinaseCrizotinibEML4-ALK fusion protein, humanEthylnitrosoureaLactamsLactams, MacrocycliclorlatinibOncogene Proteins, FusionProtein Kinase InhibitorsPyrazoles
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT07045610ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.